

#55758

Date: December 20, 2024

Subject: RXRX1 Options - Expiration Pricing Consideration

RXRX1 (adjusted Exscientia plc options) will be subject to special pricing consideration in expiration processing on December 20, 2024. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of RXRX1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

RXRX1

RXRX1 options are adjusted Exscientia plc options, adjusted November 20, 2024 (see OCC Information Memo #55579). The deliverable of RXRX1 options is:

NEW DELIVERABLE

PER CONTRACT: 1) 77 Recursion Pharmaceuticals, Inc. (RXRX) Class A Common Shares

2) Cash in lieu of 0.29 fractional RXRX Shares, less fees, if any

As of December 20, 2024, the EXAI Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating a RXRX1 price for use in expiration processing, OCC will use the following formula:

RXRX1 = 0.7729 (RXRX)

For example, if RXRX closes at 6.09, the RXRX1 price would be:

RXRX1 = 0.7729 (6.09) = 4.71

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the merger.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com.

Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com .